To inquire about our available technologies, call our office (813) 745-6828

Name & Description Number
Protein Diagnostic: Characterization of Quantum Dots for Ovarian Cancer Detection 04A064
Protein Signature: Discriminating Common Adenocarcinomas 05A014
Genetic Signature: Metastatic Melanoma Stage Identification 06B073
Plasma Protein Biomarker: Diagnosis of Ovarian Cancer 06B098
Protein Biomarker: Predicting Response to Immunosuppression in MDS 07A056
Genetic Signature: Predicting Tumor Aggressiveness 07B108
Protein Biomarker: Diagnostic Marker for AML and MPD 07B113
Genetic Signature: Malignancy Risk Signature to Predict High-Risk Normal Breast Tissues 08A016
Antibody Diagnostic: Monitoring Multiple Myeloma Progression and Recurrence 08MA005
Genetic Signature: Lymph Node Formation for Prognosis of Colorectal Cancer 09MA014
Protein Biomarker/Genetic Signature: Diagnostic for the Classification of Carcinomas of Unknown Primary Site (CUP) 10MA009
Genetic Signature: Predicting High Grade Glioma Outcomes Using Senescence Associated Genes 10MA013
Molecular Imaging Probe: Non-invasive Detection of Breast Cancer in Lymph Nodes 10MA024
Molecular Imaging Probe: Fluorescent and MRI Targeted Probes for the Melanocortin Receptor 1 on Melanomas, and Micelle Complexes for Drug Delivery 10MB069N
Genetic Signature: CREB Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking 11MA006
Protein Diagnostic: Protein-Protein Interaction (PPI) Biomarkers 11MA014
 Imaging: Digital Pathology Tool to Grade Breast Cancer Histological Images 11MA022
Molecular Imaging Probe: Surrogate Markers for Colon Adenoma and Adenocarcinoma 11MA026N
Genetic Signature: Method of Detecting MDS Using hTERT Activity 11MB061N
Molecular Imaging Probe: Intraoperative Detection of Pancreatic Cancer Using Targeted Fluorescent Probes 11MB064
Genetic Signature: Predicting Response to Cancer Immunotherapy 11MB069
Protein Signature: Method of Diagnosing Chronic Lymphocytic Leukemia 11MB072N
Protein Diagnostic: Mass Spectrometry Diagnostic for BRAF and Heat Shock Proteins 11MB087N
Genetic Signature: Five Gene Signature Predicts Overall and Recurrence-Free Survival in NSCLC 12MA023N
Genetic Signature: O-glycan Pathway Gene Signature to Determine which Ovarian Cancer Patients would have a Survival Benefit from Optimal Surgical Debulking 12MA034
Genetic Signature: Determining Prostate Cancer Recurrence Using Polymorphisms in Angiogenesis Genes 12MA045
Molecular Imaging Probe: Probes for Lung Cancer Intraoperative Guidance 12MA050N
Genetic Signature: E2F/Rb Pathway Signature to Predict Benefit from Adjuvant Chemo in NSCLC 12MA069
Molecular Imaging Probe: A Novel 18F Scaffold for Preparing Targeted PET Imaging Probes 12MB104
Protein Diagnostic: Phosphorylated STAT3 Protein as a Biomarker of Graft Versus Host Disease 13MA002
Multiplex Diagnostic: RNA Sequencing and Mass Spectrometric Method for Detecting Minimal Residual Disease in Multiple Myeloma 13MA009
Genetic Signature: Predicting Recurrence and Benefit From Adjuvant Chemotherapy in Colorectal Cancer 13MA036
Imaging: Decision Support Tool for Oncology Treatment that Analyzes Radiological Images 13MB047
Cell Imaging: Apparatus and Method for Selecting Cancer Treatment Regimens for Multiple Myeloma 13MB048N
Molecular Imaging: Texture Feature Analysis of Low-Dose CT Images for Pulmonary Nodule Diagnosis 13MB054
Molecular Imaging: Novel Imaging Software Diagnostic to Determine Survival in Glioblastoma 13MB055
Molecular Imaging: PET Probes of Radiofluorinated Carboximidamides for IDO-Targeted Imaging 13MB056N
miRNA Diagnostic: Blood Based microRNA Assay to Detect Malignant Intraductal Papillary Mucinous Neoplasms (IPMNs) 13MB078
miRNA Diagnostic: Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma 13MB080
Protein Biomarker: Expression of WEE1 and PAXIP1 to Predict Respond to WEE1 Inhibitors 14MA001
Genetic Signature: Predicting Distant Metastasis in Stage I Lung Cancer Patients Treated with Surgery 14MA008
Genetic Signature: Microarray-based Gene Expression Profiling to Predict Tumor Sensitivity to Radiotherapy 14MA052N
WEE1: Small Molecule WEE1 Inhibitor to Treat Cancer that Inhibits WEE1 Phosphorylation of H2B but not Cdc2 14MB092
Molecular Imaging: Monoacylated TLR2 Ligand Fluorescent Probe for Detection and Tumor Removal in Pancreatic Cancer Patients 15MA015 
Diagnostic: Intracellular S100A9 Alone or NLRP3 Inflammasome Activation May Be Specific Biomarkers for MDS 15MA021N 
Diagnostic: S100A9 Serum Concentration Levels Predict Lenalidomide Response Duration 15MA031N 
Molecular Imaging Probe: In vivo Positron Emission Tomography-Based Perfusion/Blood Pool Imaging Using Labeled Erythrocytes 15MB042N 
Protein Biomarker: Diagnostic for Progression of MDS to AML Using PD-1 or PD-L1 Expression 15MB065
Genetic Signature: Distinguishing Lung Carcinoma from Metastatic Head & Neck Carcinoma 16MB040
Protein Biomarker: Measuring MRE11 in Muscle-Invasive Bladder Cancer to Predict whether Cystectomy (bladder removal) would have a Better Outcome than Bladder-sparing Therapy with Chemoradiation 16MB041
Protein Biomarker: Predicting Restoration of Sensitivity to Erythropoietin in MDS Patients treated with Lenalidomide 16MB042
Molecular Imaging Probe: Novel IDO1-Targeting Cancer Diagnostic PET Imaging Agent 16MB044
miRNA Diagnostic: Signature to Predict Progression of Barrett’s Esophagus to Esophageal Dysplasia or Adenocarcinoma 16MB066
miRNA Diagnostic: miRNA Signature combined with Radiological Features for Non-invasive Early Detection of Malignancy in IPMN 17MA001
Genetic Biomarker: PTEN Loss of Expression as a Biomarker Response to GGTI-2418 Treatment 17MA025
Genetic Signature: Distinguishing Urothelial Carcinoma from Squamous Cell Carcinoma (Primary Lung Carcinoma and Metastatic Head & Neck Carcinoma) 17MB044